8-K current report · filed Nov 13, 2026

Intellia Therapeutics, Inc. (NTLA) 8-K Current Report: November 13, 2026

Item 7.01Item EX-99.1NTLA overview

Short answer

Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE).

Intellia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE)
  • Presentation materials furnished as Exhibit 99.1, providing the detailed program update
  • Event signals commercialization-readiness activity for Intellia’s lonvo-z HAE program

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted lonvo-z’s BLA with priority review and a March 10, 2027 PDUFA goal, advancing Intellia toward potential commercial launch
  • Phase 3 HAELO met primary and key secondary endpoints, including 62% attack-rate reduction and 87% fewer attack-free weeks versus placebo
  • Durability supports a one-time treatment model: 31 of 32 patients remained in long-term follow-up, with effects reported up to 4 years
  • Lonvo-z 50 mg data covered 93 treated patients, with 55% reporting infusion-related reactions and two serious adverse events
  • Commercial positioning targets chronic HAE treatment burdens, including lifetime medication use, insurance barriers and recurring administrationેણ

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Intellia Therapeutics, Inc. 8-K filings

Get the next NTLA 8-K as it lands

Follow NTLA for push alerts, or ask the research agent what this filing means.